Existing vaccines should still protect people who contract the Omicron variant from severe Covid cases, a World Health Organization (WHO) official says.
It comes as the first lab tests of the new variant in South Africa suggest it can partially evade the Pfizer jab.
Researchers say there was a “very large drop” in how well the vaccine’s antibodies neutralised the new strain.
But the WHO’s Dr Mike Ryan said there was no sign Omicron would be better at evading vaccines than other variants.
“We have highly effective vaccines that have proved effective against all the variants so far, in terms of severe disease and hospitalisation, and there’s no reason to expect that it wouldn’t be so” for Omicron, Dr Ryan, the WHO’s emergencies director, told AFP news agency.
He said initial data suggested Omicron did not make people sicker than the Delta and other strains. “If anything, the direction is towards less severity,” he said.
The new South African study – which has not yet been peer-reviewed – found the Pfizer/BioNTech vaccine may result in up to 40 times fewer neutralising antibodies against Omicron than against the original Covid strain.
But Omicron’s ability to escape vaccine antibodies is “incomplete”, said Prof Alex Sigal, a virologist at the Africa Health Research Institute, who led the research.
He said the results, based on blood tests from 12 people, were “better than I expected of Omicron”.
Prof Sigal said vaccination, combined with previous infection, could still neutralise against the variant. That suggests boosters may bring a significant benefit.
Scientists believe the previous infection, followed by vaccination or a booster, is likely to increase the neutralisation level and will probably protect people against severe disease.
More data on how well the Pfizer jab works against Omicron is expected to be released in the coming days.
There is no significant data yet on how the Moderna, Johnson & Johnson and other jabs hold up against the new variant.
